BMY (bristol myers squibb) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BMY (bristol myers squibb)

BMY 42.83

-1.3%

Oct 28 3:59 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: zax	4/25/2019 5:15:21 PM
	Read Replies (1) of 194

Bristol-Myers Squibb Company (BMY) *45.64 + 1.02 (+2.29%)* I'm in as of 4/22 @ 45.21. IMO, the Celgene acquisition is going to unleash this stock. Bristol-Myers Q1 Earnings Beat, Sales Up on Strong Eliquis April 25, 2019 Bristol-Myers Squibb Company’s BMY reported better-than-expected results for the first quarter of 2019 on the stellar performance of its blood thinner drug, Eliquis. First-quarter 2019 earnings of $1.10 per share beat the Zacks Consensus Estimate by a penny and surpassed the year-ago quarter’s earnings of 94 cents. Total revenues of $5.92 billion surpassed the Zacks Consensus Estimate of $5.80 billion and increased 14% from $5.2 billion recorded in the year-ago period. Continued strong sales of Opdivo and Eliquis contributed to the top line in the reported quarter. Shares are up in pre-market trading on better-than-expected results for the first quarter. However, Bristol-Myers’ shares have decreased 9.3% in the past six months compared with the industry’s decline of 1.0%. </snip> Read the rest here: finance.yahoo.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next